Dr. Daniel “Danni” Frimannsson is a seasoned biotechnology leader with deep expertise in nucleic acid therapeutics, delivery technologies, and platform development for RNA-based medicines. At Axelyf, he leads the company’s efforts in RNA design, delivery biology, and technological innovation to enable next-generation genetic medicines.

Prior to joining Axelyf, Danni held senior scientific and leadership roles in emerging biotech companies focused on mRNA and delivery modalities. He has extensive experience working at the intersection of discovery and development—spanning mRNA therapeutics, codon optimization, untranslated region discovery, and vaccine design—as well as hands-on engagement with lipid nanoparticle (LNP) and AAV delivery systems. Throughout his career, Danni has been recognized for his ability to blend strategic thinking with practical execution, mentoring teams, and scaling operational capabilities in fast-moving technology environments. His commitment to scientific rigor and translational impact underscores Axelyf’s mission to unlock transformative genetic medicines for patients.